Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Hospital Clinic Barcelona
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Clinic Barcelona (17)
2024
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Nature Communications, Vol. 15, Núm. 1
2023
-
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221
-
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
Cell Reports Medicine, Vol. 4, Núm. 3
2022
-
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10
-
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Journal for immunotherapy of cancer, Vol. 10, Núm. 3
2021
-
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment
Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 434-449
-
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
Cancer Immunology Research, Vol. 9, Núm. 12, pp. 1476-1490
2019
-
Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study
Medical Oncology, Vol. 36, Núm. 3
2018
-
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer
Clinical Genitourinary Cancer, Vol. 16, Núm. 6, pp. e1133-e1139
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
2017
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
2014
2013
-
Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)
Clinical and Translational Oncology, Vol. 15, Núm. 9, pp. 698-704
2011
2009
2006
-
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer
International Journal of Gynecological Cancer, Vol. 16, Núm. 1, pp. 71-76